Company news

Lexicon Pharmaceuticals, Inc. news in 2026

Lexicon Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates

November 5, 2026

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

October 29, 2026

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

October 23, 2026

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

October 21, 2026

LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities

September 25, 2026

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

September 1, 2026

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

August 31, 2026

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

August 24, 2026

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

August 7, 2026

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

July 27, 2026

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

June 3, 2026

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

May 7, 2026

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

May 4, 2026

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

April 17, 2026

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

March 23, 2026

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

March 23, 2026

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

March 11, 2026

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

March 4, 2026

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

March 3, 2026

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

February 26, 2026

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 6, 2026

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

January 29, 2026

Lexicon Announces Proposed Public Offering of Common Stock

January 29, 2026

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

January 23, 2026

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

January 21, 2026

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

January 9, 2026

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Calls in 2026

Decks in 2026